These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22487716)

  • 21. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical expenditure compared across countries.
    van Mosseveld C
    Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical pricing, cost containment and new treatments for rare diseases in children.
    Stella P; Gold-von Simson G
    Orphanet J Rare Dis; 2014 Oct; 9():152. PubMed ID: 25348640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value-based pricing of drugs in the UK.
    Webb DJ; Walker A
    Lancet; 2007 Apr; 369(9571):1415-1416. PubMed ID: 17467498
    [No Abstract]   [Full Text] [Related]  

  • 25. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

  • 28. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

  • 29. The economic value of companion diagnostics and stratified medicines.
    Blair ED; Stratton EK; Kaufmann M
    Expert Rev Mol Diagn; 2012 Nov; 12(8):791-4. PubMed ID: 23249194
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 31. Comments on "Presidential address: advocacy as leadership".
    Clary C; Loebel A; Lombardo I; Alphs L; Binneman B; Vanderburg D; Warrington L; Parsons B; Fogel I; Herman B; Roberts H; Templeton H; Hughes D; Chappell P; Feltner D; Tobias K; Watsky E; Ramey T; Rappard F
    Am J Psychiatry; 2007 Feb; 164(2):346; author reply 346. PubMed ID: 17267802
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceutical Greed and Its Consequences.
    Jacobs HE
    Conn Med; 2016 May; 80(5):315-6. PubMed ID: 27328583
    [No Abstract]   [Full Text] [Related]  

  • 33. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 35. Paces of Costly Care: Rare Disease Drug Access in Canada.
    McGuire M
    Med Anthropol; 2020; 39(4):319-332. PubMed ID: 30892965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
    Quartey G; Wang J
    Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 39. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.